Matches in Nanopublications for { ?s ?p "[Approximately 50% of essential thrombocythaemia and primary myelo-fibrosis patients do not have a JAK2 V617F mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP97251.RA0UoBitaKzhKZWA9eXFwMsY_bh_dS4MnyTBAGbjNCujA130_assertion description "[Approximately 50% of essential thrombocythaemia and primary myelo-fibrosis patients do not have a JAK2 V617F mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP97251.RA0UoBitaKzhKZWA9eXFwMsY_bh_dS4MnyTBAGbjNCujA130_provenance.
- assertion description "[Approximately 50% of essential thrombocythaemia and primary myelo-fibrosis patients do not have a JAK2 V617F mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Approximately 50% of essential thrombocythaemia and primary myelo-fibrosis patients do not have a JAK2 V617F mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP164436.RAnsjXWXa5Cnk6wszScjeaGzAKgcDHwEpbvddgioWw9jY130_assertion description "[Approximately 50% of essential thrombocythaemia and primary myelo-fibrosis patients do not have a JAK2 V617F mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP164436.RAnsjXWXa5Cnk6wszScjeaGzAKgcDHwEpbvddgioWw9jY130_provenance.